T Cell, NK Cell Differentiation from Creative Bioarray

Product Specs
ItemT Cell, NK Cell Differentiation
CompanyCreative Bioarray
Price Supplier Page
Catalog NumberT Cell, NK Cell Differentiation

Creative Bioarray

Phone: 1-631-626-9181(USA)
44-208-123-7131(Europe)

Email: info@creative-bioarray.com

Website: https://www.creative-bioarray.com/

(1) Tumor-intrinsic redox programming drives an SPP1-CD44 axis of immune suppression in uveal melanomaRedox BiologyMarch 1, 2026Tongxin Ge, Yun Yang, Wenyue Zhang, Mengyao Li, Xiang Gu, Ludi Yang, Renbing Jia, Xingyun Wang, Xianqun Fan, Ai Zhuangrecombinant human SPP1 (Gibco, 120-35) or 10 μg/mL anti-CD44 antibody (Creative Biolabs, TAB-128CL). T cell proliferation and cytotoxic function were assessed by Ki-67 staining (FITC) and IFN-γ staining (PC7)

(2) Cancer Vaccine Targeting Mutated GNAQ-Expressing Uveal MelanomaCancers (Basel)January 31, 2026Vitali Alexeev, Mizue Terai, Sergei Koshkin, Olga Igoucheva, Takami SatoFACS system. Data were analyzed using GuavaSoft 2.7 software. 2.6. Immuno-Sequencing and Analysis of T Cell Repertoire Evaluation and analysis of the T cell repertoire of the UM-recognizing vaccine-activated

(3) CAR-T cell therapy targeting MUC17 in gastric tumorsJournal for ImmunoTherapy of CancerNovember 18, 2025Sangwoo Park, Cassidy E Ho, Filippo Birocchi, Alexandra N Wolff, Amanda A Bouffard, Christopher Kelly, Diego Salas-Benito, Giulia Escobar, Adele Mucci, Trisha Berger, et al.classified as ‘non-human subjects research’. Mice used in vivo experiments were randomized prior to CAR T cell administration. Primary cells and cell lines GSU (Creative Bioarray), NUGC4 (Creative Bioarray), and

(4) Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeJournal for ImmunoTherapy of CancerJuly 30, 2025David N Ciccone, Fu-Shan Kuo, Scott Boiko, Samantha Carreiro, Neelu Kaila, Joshua J McElwee, Peter J Tummino, Christine LohCat. #KA1014 and Total IgG ELISA Kit from Creative Diagnostics, Cat. #DEIA8704). DNP-Ficoll induced T-cell independent antibody response in vivo study Female C57BL/6 mice (8–10 weeks) were used in this study.

(5) Single‐Cell Sequencing Reveals That CD4 + T Cells Eliminate Senescent Prostate Epithelium to Delay Progression of Benign Prostatic HyperplasiaAging CellJuly 27, 2025Zheng Li, Xiaofei Wang, Zhifu Liu, Senmao Li, Zhenan Zhang, Chenchen Huang, Yixiao Liu, Xingxing Tang, Jiaen Zhang, Peimin Zhou, et al.Creative Biolabs) in the upper chamber. This setup was used to evaluate the role of CXCL13 in CD4+ T cell migration toward senescent epithelial cells. 2.23 RNA Sequencing (RNA‐Seq) Data Processing and Analysis

(6) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignanciesCellJanuary 23, 2025Zhenhua Chen, Chengwu Zeng, Lu Yang, Yuan Che, Meiling Chen, Lillian Sau, Bintao Wang, Keren Zhou, Yu Chen, Ying Qing, et al.blinatumomab (Tandem scFv BSAB-L002-200222, Creative BioLabs). Blinatumomab is a CD3-CD19 bispecific T cell engager formed by linking a distinct pair of immunoglobulins (Igs) variable domains through a 25-amino

(7) Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering systemPLOS ONEAugust 27, 2024Peter S. Chang, Yi-Chun Chen, Wei-Kai Hua, Jeff C. Hsu, Jui-Cheng Tsai, Yi-Wun Huang, Yi-Hsin Kao, Pei-Hua Wu, Po-Nan Wang, Yi-Fang Chang, et al.(E:T = 1:1). For the in vivo assay, mouse plasma samples were collected on days 2, 5, 8, and 14 after T cell injection. IFN-γ (Thermo), TNF-α (Thermo), IL-6 (Thermo), and IL-2 (BioLegend) were quantified by ELISA

(8) Antibody‐Conjugated Magnetic Nanoparticle Therapy for Inhibiting T‐Cell Mediated InflammationAdvanced ScienceDecember 31, 2023Mahbub Hasan, Jong‐Gu Choi, Hafeza Akter, Hasung Kang, Meejung Ahn, Sang‐Suk Leetransplantation and cytokine‐releasing syndromes such as those observed in COVID‐19. Further, the CD3‐specific T cell activation model is promising in elucidating the mechanism of T cell inhibition. 4 Experimental Section Materials Absolute

(9) Design and preclinical testing of an anti‐CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemiaJournal of Cellular and Molecular MedicineOctober 1, 2023Adrian Bogdan Tigu, Catalin Sorin Constantinescu, Patric Teodorescu, David Kegyes, Raluca Munteanu, Richard Feder, Mareike Peters, Ioana Pralea, Cristina Iuga, Diana Cenariu, et al.current manuscript is to design and afterwards investigate in the preclinical setting an anti‐CD41 CAR T cell, both in vitro and in vivo. 2 MATERIALS AND METHODS 2.1 Design of the CAR construct The full length

(10) Diffuse Large B-Cell Lymphoma of the Frontal Sinus: A Case ReportHematology ReportsSeptember 12, 2023Anastasia Urbanelli, Francesca Testi, Giuseppe Riva, Giancarlo PecorariAugust 2021, the patient underwent lymphocyte apheresis for CAR-T (chimeric-antigen-receptor-engineered T cell) therapy (Creative Biolabs, London, UK). In September, radiotherapy and concurrent therapy with pixantrone

(11) mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor ImmunityCancer immunology researchJuly 5, 2023Nirschl CJ, Brodkin HR, Domonkos C, Dwyer CJ, Hicklin DJ, Ismail N, Seidel-Dugan C, Steiner P, Steuert Z, Sullivan JM, et al.under accession number PRJNA952625. The clonality index specific for characterizing the situation of T-cell clonal proliferation was calculated on the basis of the following equation where pi is the proportion

(12) Reply to Herrmann et al.: The BTN3A isoform BTN3A1 is responsible for phosphoantigen-induced Vγ9Vδ2 T cell activationProceedings of the National Academy of SciencesMay 16, 2023Jiaqing Zhou, Jingjing Zhang, Zhenghua Zhang, Lei Shensystem was stimulated with pAgs throughout the study (2). It has been shown that pAg-induced Vγ9Vδ2 T cell activation is dependent on BTN3A1, not BTN3A2 and BTN3A3 in the BTN3A family (3–5). Based on the data

(13) G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinomaNature communicationsFebruary 2, 2023Lam MSY, Reales-Calderon JA, Ow JR, Aw JJY, Tan D, Vijayakumar R, Ceccarello E, Tabaglio T, Lim YT, Chien WL, et al.donor. Experiments were conducted only if at least 50% of CD3+ cells expressed the S183-191 TCR. CAR-T cell generation scFv-CD28-CD3ζ-T2A-RFP-anti-CD133 plasmid (Creative Biolabs, USA) was used to generate CD133-directed

(14) Histone Deacetylase Inhibitors Restore Cancer Cell Sensitivity towards T Lymphocytes Mediated Cytotoxicity in Pancreatic CancerCancers (Basel)July 29, 2022Chin-King Looi, Li-Lian Gan, Wynne Sim, Ling-Wei Hii, Felicia Fei-Lei Chung, Chee-Onn Leong, Wei-Meng Lim, Chun-Wai Maihuman T-Activator CD3/CD28 Dynabeads® (Thermo Fisher Scientific Inc., Waltham, MA, USA). On Day 3 of T cell activation, CTLs were harvested, and CD3/CD28 Dynabeads® were removed magnetically. Anti-EpCAM/anti-CD3

(15) TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancerJournal for ImmunoTherapy of CancerJuly 11, 2022David B Rosen, Anne Månsson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Enping Hong, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zúñiga, Kathy Bang, et al.presence of 1 nM of a CD3–CD20 bispecific antibody (Creative Biolabs) in a flow cytometry assay. γδ T cell cytotoxicity assays used Raji target cells as described above or Daudi target cells. Additionally, supernatants

(16) Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunityBrainNovember 29, 2021Marie Liebmann, Lisanne Korn, Claudia Janoschka, Stefanie Albrecht, Sarah Lauks, Alexander M Herrmann, Andreas Schulte-Mecklenbeck, Nicholas Schwab, Tilman Schneider-Hohendorf, Maria Eveslage, et al.ultra-high performance LC-quadrupole time-of-flight MS (UHPLC-QTOF-MS, WatersCorp). In addition, CD4+ T-cell samples were measured at the IZKF Core Unit Proteomics using Pall Nanosep® 10K Omega units (3.5 kDa

(17) T cell exhaustion drives osteosarcoma pathogenesisAnnals of translational medicineSeptember 1, 2021Sun CY, Zhang Z, Tao L, Xu FF, Li HY, Zhang HY, Liu W.allogeneic PBMCs (stimulators) at 1:1, 2:1, and 5:1 ratio. CD14+ antigen was present in all wells. T cell proliferation was calculated by analyzing the CFSE dilution of the responders after 72 h. Where indicated,

(18) 4-1BB costimulation promotes bystander activation of human CD8 T cellsEuropean journal of immunologyMarch 1, 2021Reithofer M, Rosskopf S, Leitner J, Battin C, Bohle B, Steinberger P, Jahn-Schmid B.reporter cells expressing 4‐1BB or control‐triple parameter reporter cells were cultured with or without T‐cell stimulator cells (TCS) at a ratio of 2.5:1. Urelumab (purchased from Creative Biolabs, Shirley, NY)

(19) Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastomaNature cancerJanuary 1, 2021Ma W, Wang Y, Zhang R, Yang F, Zhang D, Huang M, Zhang L, Dorsey JF, Binder ZA, O'Rourke DM, et al.renilla luciferases were detected using a Dual-Luciferase Reporter Assay System (Promega; E1980). Mouse T cell isolation and transduction. The rLuc-tdTomato sequence was subcloned into the pMSGV vector (Creative Biolabs

(20) MLLT6 maintains PD-L1 expression and mediates tumor immune resistanceEMBO reportsDecember 3, 2020Sreevalsan S, Döring M, Paszkowski-Rogacz M, Brux M, Blanck C, Meyer M, Momburg F, Buchholz F, Theis M.FITC mouse anti‐human CD69 (BD PharMingen, 557049). Bi‐specific Antibodies: Recombinant anti‐EpCAM‐CD3 bi‐specific T cell engagers were from Creative Biolabs (BITE‐L022). Recombinant anti‐HER2 x anti‐CD3 and anti‐EGFR x anti‐CD3

Be the First to Write a Review!

T Cell, NK Cell Differentiation from Creative Bioarray

Description

Creative Bioarray

Citations (27)

Reviews

T Cell, NK Cell Differentiation from Creative Bioarray

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map